Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Hematological cancer

Gene classifier helps identify therapy for leukemia

Nature Reviews Clinical Oncology volume 9, page 4 (2012)Cite this article

Subjects

Scientists have developed a 38-gene classifier that can accurately predict patients who are at risk of developing leukemia. Gene expression was assessed in CD34+ cells from patients who developed therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after transplantation and compared the results with control patients who did not develop t-MDS/AML. In an independent cohort, this classifier accurately distinguished patients who developed t-MDS/AML from those who did not, indicating the use of this classifier for determining those at risk for this complication.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Li, L. et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell 20, 591–605 (2011)

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gene classifier helps identify therapy for leukemia. Nat Rev Clin Oncol 9, 4 (2012). https://doi.org/10.1038/nrclinonc.2011.185

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.185

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer